Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 105,597 | 145,647 | 123,554 | 293,828 | 140,406 |
| Marketable Securities | 264,930 | 400,576 | 516,598 | 320,966 | 472,213 |
| TOTAL | $379,594 | $554,686 | $651,295 | $626,286 | $617,547 |
| Non-Current Assets | |||||
| PPE Net | 48,200 | 102,654 | 123,023 | 120,098 | 77,045 |
| Investments And Advances | 32,014 | 48,507 | 115,041 | 330,532 | 163,443 |
| Other Non-Current Assets | 31,051 | 44,182 | 48,202 | 50,490 | 50,245 |
| TOTAL | $111,265 | $195,343 | $286,266 | $501,120 | $290,733 |
| Total Assets | $490,859 | $750,029 | $937,561 | $1,127,406 | $908,280 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 12,966 | 4,817 | 3,917 | 3,207 | 9,396 |
| Accrued Expenses | 40,411 | 28,126 | 28,755 | 29,057 | 28,021 |
| Other current liabilities | 411 | 1,576 | 4,356 | 9,486 | 5,773 |
| TOTAL | $53,788 | $34,519 | $37,028 | $46,738 | $49,285 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | 4,988 | 6,095 |
| Other Non-Current Liabilities | 54,247 | 60,558 | 67,281 | 71,216 | 1,062,457 |
| TOTAL | $54,247 | $60,558 | $67,281 | $150,881 | $1,151,523 |
| Total Liabilities | $108,035 | $95,077 | $104,309 | $197,619 | $1,200,808 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 14,761 | 12,705 | 12,480 | 12,269 | N/A |
| Common Shares | 29 | 25 | 25 | 24 | 2 |
| Retained earnings | -1,345,106 | -1,002,112 | -767,480 | -584,362 | -334,143 |
| Other shareholders' equity | 291 | -94 | -7,599 | -1,623 | 256 |
| TOTAL | $382,824 | $654,952 | $833,252 | $929,787 | $-292,528 |
| Total Liabilities And Equity | $490,859 | $750,029 | $937,561 | $1,127,406 | $908,280 |